SCHEMBL1640452

SCHEMBL1640452

O=C(Nc1nccs1)c1cn(Cc2ccccc2)c(=O)cc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
LMNA P02545 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
KMT2A Q03164 1/20 0.53
CYP1A2 P05177 1/20 0.52
KCNMA1 Q12791 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
TDP1 Q9NUW8 2/20 0.51
MAPK1 P28482 1/20 0.51
NPC1 O15118 5/20 0.50
RAB9A P51151 4/20 0.50
KDM4E B2RXH2 2/20 0.50
GAA P10253 1/20 0.48
METAP2 P50579 1/20 0.48
METAP1 P53582 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HRH1 P35367 1/20 0.47
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641863 0.83 TSHR (0.48) ALDH1A1LMNAMEN1KMT2ACYP1A2
SCHEMBL1641962 0.81 NPC1 (0.54) ALDH1A1MEN1MAPTKMT2ACYP1A2
SCHEMBL1606612 0.81 NPSR1 (0.68) ALDH1A1LMNANPSR1MEN1MAPT
SCHEMBL1642053 0.81 MAPT (0.59) ALDH1A1LMNAMEN1MAPTKMT2A
SCHEMBL1607575 0.78 ALDH1A1 (0.57) ALDH1A1LMNANPSR1MEN1MAPT
SCHEMBL1607719 0.78 ALDH1A1 (0.54) ALDH1A1LMNANPSR1MEN1MAPT
SCHEMBL1607364 0.78 ALDH1A1 (0.58) ALDH1A1LMNANPSR1MEN1MAPT
SCHEMBL1606811 0.78 ALDH1A1 (0.56) ALDH1A1LMNANPSR1MEN1MAPT
SCHEMBL1641964 0.77 KDM4E (0.54) ALDH1A1LMNAMEN1MAPTKMT2A
SCHEMBL1641774 0.77 ALDH1A1 (0.53) ALDH1A1LMNAMAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 ALDH1A1 227/4885LMNA 3462/4885NPSR1 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.